Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
    Datensatz exportieren als...
  • BibTeX
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
The New England journal of medicine, 2020-01, Vol.382 (2), p.120-129
2020

Details

Autor(en) / Beteiligte
Titel
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
Ist Teil von
  • The New England journal of medicine, 2020-01, Vol.382 (2), p.120-129
Ort / Verlag
United States: Massachusetts Medical Society
Erscheinungsjahr
2020
Link zum Volltext
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
  • Patients who had undergone successful TAVR were randomly assigned to receive either a rivaroxaban-based antithrombotic regimen or an antiplatelet-based antithrombotic regimen. At 17 months, the primary outcome of death or thromboembolic complications occurred more frequently with rivaroxaban.
Sprache
Englisch
Identifikatoren
ISSN: 0028-4793, 1533-4406
eISSN: 1533-4406
DOI: 10.1056/NEJMoa1911425
Titel-ID: cdi_proquest_miscellaneous_2315086640
Format
–
Schlagworte
9NDF7JZ4M3 (Rivaroxaban), A74586SNO7 (Clopidogrel), Aged, Aged, 80 and over, Aorta, Aortic valve stenosis, Aspirin, Aspirin - adverse effects, Aspirin - therapeutic use, Aspirin/adverse effects/therapeutic use, Atrial Fibrillation - drug therapy, Bleeding, Cardiac arrhythmia, Cardiovascular & respiratory systems, Cardiovascular Diseases - mortality, Care and treatment, Clopidogrel, Clopidogrel - adverse effects, Clopidogrel - therapeutic use, Clopidogrel/adverse effects/therapeutic use, Complications and side effects, Confidence intervals, Death, Drug Therapy, Combination, Embolisms, Factor Xa Inhibitors, Factor Xa Inhibitors - adverse effects, Factor Xa Inhibitors - therapeutic use, Factor Xa Inhibitors/adverse effects/therapeutic use, Female, Heart Valve Prosthesis, Heart valve replacement, Hemorrhage - chemically induced, Human health sciences, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Male, Patient outcomes, Platelet Aggregation Inhibitors, Platelet Aggregation Inhibitors - adverse effects, Platelet Aggregation Inhibitors - therapeutic use, Platelet Aggregation Inhibitors/adverse effects/therapeutic use, R16CO5Y76E (Aspirin), Rivaroxaban, Rivaroxaban - adverse effects, Rivaroxaban - therapeutic use, Rivaroxaban/adverse effects/therapeutic use, Safety, Sciences de la santé humaine, Statistical analysis, Systèmes cardiovasculaire & respiratoire, Testing, Thromboembolism, Thromboembolism - mortality, Thrombosis, Transcatheter Aortic Valve Replacement

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX